Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I MAD Study of AZD8233 in Dyslipidemia
NCT04155645Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Primary completion
- Jun 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD8233 in dyslipidemia (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs), Vital sign: Systolic blood pressure (SBP) and 9 more. Started Nov 2019; status: completed.
02
Drugs
AZD8233
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04155645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155645.